|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. For example, here is how to disable FireFox ad content blocking while on Silicon Investor.|
I didn't see any thread for ROCM so I thought I would start one.
Rochester Medical develops and manufactures a broad line of
innovative latex-free urinary continence care products
for the home care and hospital care markets. The Company markets its products under its own ROCHESTER MEDICAL(R) brand and through private label arrangements.
On May 3, 1999, results from a multi-center 12-month clinical trial announced at the 20th Annual Society of Urodynamics and Female Urology indicated that ROCM's new FEMSOFT(R) Insert is highly effective and has a high degree of patient acceptance and satisfaction. Dr. Larry T. Sirls (Department of Urology, William Beaumont Hospital, Royal Oak, Mich.), one of the principal investigators in the trial, said the FemSoft Insert "will likely become an important treatment option" in physician care for female stress incontinence.
During a separate panel discussion on the range of incontinence treatments at the 20th Annual Society of Urodynamics and Female Urology sessions, Dr. Michael Kennelly (a practicing urologist with McKay Urology Associates in Charlotte, N.C.) said that clinical data from the FemSoft Insert study is very promising: "We may indeed be witnessing the emergence of an effective and truly patient-friendly treatment modality for female stress incontinence."
Financial information for the company is available via the SEC's EDGAR system at sec.gov
|© 2019 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|